deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT07138196

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

A Phase 1b, Open-label Dose Escalation Study to Evaluate the Safety, Pharmacodynamic, Pharmacokinetic and Preliminary Efficacy of Q702 in Subjects With Relapsed or Refractory Active Chronic Graft-versus-Host Disease (cGVHD)

Sponsor: Qurient Co., Ltd.

Conditions Chronic Graft-Versus-Host Disease
Interventions Adrixetinib
Updated 2 times since 2025 Last updated: Dec 24, 2025 Started: Dec 23, 2025 Primary completion: Oct 23, 2029 Completion: Oct 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07138196, this PHASE1 trial focuses on Chronic Graft-Versus-Host Disease and remains actively recruiting participants. Sponsored by Qurient Co., Ltd., it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshotNot Yet Recruiting~Jan 2026 – present · 6 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  2. Sep 2025 — Jan 2026 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Qurient Co., Ltd.
Data source: Qurient Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations